Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy

Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy

Purpose: Myeloproliferative neoplasms (MPNs) have been associated with increased systemic levels of vascular endothelial growth factor (VEGF). This study investigated an association between systemic busulfan for treatment of MPN and the requirement for intravitreal anti-VEGF injections for treatment...

Full description

Bibliographic Details
Main Authors: Lauren A. Dalvin, Timothy W. Olsen, Sophie J. Bakri, Kristen McCullough, Ayalew Tefferi, Aref Al-Kali
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:American Journal of Ophthalmology Case Reports
Subjects:
Anti-Vascular endothelial growth factor
Busulfan
Diabetic macular edema
Macular degeneration
Myeloproliferative disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2451993622003000

Internet

http://www.sciencedirect.com/science/article/pii/S2451993622003000

Similar Items